Please assess the completion status of the following clinical trial:

Trial Title: [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥18 years old.~2. Adequate organ function (obtained within 14 days prior to PET scan \[Part 1, Part 2, and Part 3 ONLY\] or within 28 days prior to PET scan \[Part 4 ONLY\]) as evidenced by:~1. ANC ≥ 1.5 X 10\^9/L w/o myeloid growth factor support for 7 d preceding lab assessment~2. Hgb ≥ 9 g/dL (90 g/L); \< 9 g/dL (\< 90 g/L) is acceptable if Hgb is corrected to ≥ 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan~3. Platelet count ≥ 100 X 10\^9/L w/o blood transfusions for 7 d preceding lab assessment~4. Bilirubin ≤ 1.5 X ULN except for pts w/ documented history of Gilbert's disease~5. ALT and AST ≤ 2.5 X ULN~6. Alkaline phosphatase (AP) ≤ 3 X ULN~7. Women of childbearing potential (WCBP): negative serum pregnancy test~   3. Ability to stand up and climb two steps with minimal assistance.~   4. Ability to understand and the willingness to sign a written informed consent document.~   5. (Part 2, intracranial tumor patients ONLY) (a) Radiographical or pathological evidence of newly-diagnosed intracranial tumor that is status-pre surgical resection, or (b) Radiographical or pathological evidence of progressive/recurrent intracranial tumor, (c) Question of pseudoprogression vs. true progression on most recent standard-of-care brain MRI, or (d) Evidence on the most recent standard-of-care brain MRI scan of intracranial metastasis/metastases in a patient with known extracranial primary cancer.~   6. (Part 3, GBM patients ONLY) Any patient with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM, molecular GBM, diffuse astrocytomas with molecular features of GBM, H3K27M midline gliomas, gliosarcomas, or any other WHO Grade IV glioma) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan.~   7. (Part 3, GBM patients ONLY) Life expectancy of ≥ 6 months.~Exclusion Criteria:~1. Known allergy to adhesive tapes or other skin adhesives used in medical care~2. Subjects with the following co-morbid disease or incurrent illness:~   1. With known cirrhosis diagnosed with Child-Pugh Class A or higher liver disease.~  2. Severe/uncontrolled inter-current illness within the previous 28 days prior to PET scan~  3. Patients who have implantable devices that are contra-indicated for MRI~  4. Bleeding disorder~  5. Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.~  6. (Healthy volunteers ONLY - Part 1 and Part 4) prior or current malignancy~  7. (Healthy volunteers ONLY - Part 1 and Part 4) known kidney disease~3. Pregnant or nursing participants~4. History of allergic reactions to gadolinium-based MRI contrast agent~5. (Part 2, intracranial tumor patients ONLY) Other chemotherapy (besides what is being used to treat the intracranial tumor)~6. (Part 3, GBM patients ONLY) Has already begun therapy, prior to the first of two \[18F\]DASA-23 PET/MRI scans.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group I ([18F]DASA-23, PET) (Type: ACTIVE_COMPARATOR): Healthy volunteers receive \[18F\]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
- Group II ([18F]DASA-23, PET) (Type: EXPERIMENTAL): Intracranial tumor participants receive \[18F\]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
- Group III ([18F]DASA-23, PET) (Type: EXPERIMENTAL): Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one \[18F\]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final \[18F\]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
- Group IV ([18F]DASA-23, PET) (Type: ACTIVE_COMPARATOR): Healthy volunteers receive \[18F\]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues